Skip to main content

Drug Interactions between repotrectinib and Stalevo 100

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

levodopa entacapone

Applies to: Stalevo 100 (carbidopa / entacapone / levodopa) and Stalevo 100 (carbidopa / entacapone / levodopa)

The side effects of levodopa may be increased when it is used in combination with entacapone. You may need a dose adjustment if you have been taking levodopa and are starting or stopping treatment with entacapone. Contact your doctor if your condition changes or if you experience movement difficulties, increased drowsiness, dizziness, lightheadedness, flushing, and/or fainting. Avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

levodopa repotrectinib

Applies to: Stalevo 100 (carbidopa / entacapone / levodopa) and repotrectinib

Consumer information for this interaction is not currently available.

MONITOR: Polyneuropathy has been reported during treatment with levodopa/carbidopa combinations, and concurrent use of other medications that are also associated with this adverse effect may potentiate the risk and/or severity of nerve damage. Polyneuropathy has most commonly been observed in patients receiving levodopa/carbidopa by continuous intestinal infusion, with a frequency of up to 5.8% in clinical trials. Cases were generally consistent with axonal polyneuropathy, manifested as sensory or sensorimotor neuropathies, with subacute or chronic onset. Reported symptoms primarily included numbness, tingling, decreased sensation, weakness, and pain in the legs, hands, feet, and extremities. Many of these patients had deficiencies in folic acid, vitamin B12 and vitamin B6 as well as elevated homocysteine levels. However, there was insufficient information to determine the potential role of vitamin deficiencies in the etiology of neuropathy associated with the treatment. It is also unknown whether there is a causal relationship between polyneuropathy and treatment with levodopa/carbidopa combinations.

MANAGEMENT: Before initiating treatment with enteral formulations of levodopa/carbidopa, the manufacturers recommend evaluating patients for history or signs of polyneuropathy and known risk factors such as diabetes mellitus, hypothyroidism, or concomitant use of other medications associated with polyneuropathy. For patients with preexisting polyneuropathy, the benefits of treatment should be carefully weighed against the potential risks, including the potential for impaired mobility. Plasma concentrations of vitamin B12, vitamin B6, homocysteine, methylmalonic acid, and folic acid should be obtained at baseline and at regular intervals during treatment. Patients who develop symptoms of peripheral neuropathy and low plasma concentrations of vitamin B6 and/or vitamin B12, or elevated homocysteine or methylmalonic acid concentrations, may benefit from vitamin supplementation. Physicians should carefully evaluate if a dose adjustment is warranted and assess the benefit versus risk of continued treatment.

References

  1. "Product Information. Duopa (carbidopa-levodopa)." AbbVie US LLC (2022):
  2. "Product Information. Duodopa (carbidopa-levodopa)." AbbVie Corporation (2022):
  3. "Product Information. Duodopa (carbidopa-levodopa)." AbbVie Pty Ltd 18 (2021):

Drug and food interactions

Major

repotrectinib food

Applies to: repotrectinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations and adverse effects of repotrectinib. According to prescribing information, repotrectinib is primarily metabolized by CYP450 3A4, and is also a substrate of P-gp in vitro. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with repotrectinib and grapefruit juice but has been reported for other CYP450 3A4 inhibitors. Drug interaction studies have shown that the administration of repotrectinib with itraconazole, a potent CYP450 3A4 and P-gp inhibitor, increased the peak plasma concentration (Cmax) and systemic exposure (AUC) of repotrectinib by 1.7-fold and 5.9-fold, respectively. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to repotrectinib may increase the risk of adverse reactions such as dizziness, fatigue, cognitive disorders, ataxia, dysgeusia, peripheral neuropathy, muscular weakness, and dyspnea as well as more serious adverse effects such as interstitial lung disease/pneumonitis, liver transaminase elevations, myalgia with creatinine phosphokinase (CPK) elevation, hyperuricemia, and skeletal fractures.

MANAGEMENT: The manufacturer advises that concomitant use of repotrectinib with grapefruit, grapefruit juice, or supplements that contain grapefruit should be avoided.

References

  1. "Product Information. Augtyro (repotrectinib)." Bristol-Myers Squibb ORIG-1 (2023):
Moderate

levodopa food

Applies to: Stalevo 100 (carbidopa / entacapone / levodopa)

Alcohol can increase the nervous system side effects of levodopa such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with levodopa. You may experience reduced effectiveness of levodopa in the presence of foods or enteral (tube) feedings with a high protein content. This may make the symptoms of Parkinson's disease worse. Talk with your doctor or nutrition counselor about the best foods to eat while you are taking this medication. Contact your doctor if your condition changes.

Switch to professional interaction data

Moderate

entacapone food

Applies to: Stalevo 100 (carbidopa / entacapone / levodopa)

Alcohol can increase the nervous system side effects of entacapone such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with entacapone. Do not use more than the recommended dose of entacapone, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Moderate

levodopa food

Applies to: Stalevo 100 (carbidopa / entacapone / levodopa)

Levodopa and multivitamin with minerals should not be taken orally at the same time. Products that contain iron may interfere with the absorption of levodopa and reduce its effectiveness. You should separate the dosing of these medications by as much as possible. Contact your doctor if your Parkinson symptoms worsen. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.